Phase 2 Multicenter, Double-blind, Randomized, Parallel-Group, Vehicle-Controlled Study to Evaluate the Efficacy, Safety, and Local Tolerability of G001 in Patients With Osteoarthritis (OA) of the Knee
Latest Information Update: 25 Apr 2024
Price :
$35 *
At a glance
- Drugs G 001 (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Sponsors BUZZZ Pharmaceuticals
- 13 Apr 2023 Status changed from recruiting to completed.
- 23 Aug 2021 New trial record